Business Segments · Consolidated revenues
Life Sciences Solutions — Consolidated revenues
Thermo Fisher Scientific Life Sciences Solutions — Consolidated revenues decreased by 76.0% to $2.64B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 74.6%, from $10.36B to $2.64B. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityStable
First reportedQ1 2016
Last reportedQ1 2026May 1, 2026
Rolls up toTotal Revenue
How to read this metric
An increase reflects strong market demand and successful product adoption, while a decrease signals market saturation or competitive pressure.
Detailed definition
The total gross income generated by the Life Sciences Solutions segment from the sale of reagents, instruments, and cons...
Peer comparison
Standard top-line metric used across all public companies to measure segment scale.
Metric ID:
tmo_segment_life_sciences_solutions_consolidated_revenuesHistorical Data
37 periods
| Q2 '21 | Q2 '21 | Q3 '21 | Q3 '21 | Q4 '21 | Q4 '21 | Q1 '22 | Q1 '22 | Q2 '22 | Q2 '22 | Q3 '22 | Q3 '22 | Q4 '22 | Q4 '22 | Q1 '23 | Q1 '23 | Q2 '23 | Q2 '23 | Q3 '23 | Q3 '23 | Q4 '23 | Q4 '23 | Q1 '24 | Q1 '24 | Q2 '24 | Q2 '24 | Q3 '24 | Q3 '24 | Q4 '24 | Q4 '24 | Q1 '25 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $9.27B | $3.56B | $9.33B | $3.72B | $10.7B | $4.15B | $11.82B | $4.23B | $10.97B | $3.29B | $10.68B | $2.96B | $11.45B | $3.05B | $10.71B | $2.61B | $10.69B | $2.46B | $10.57B | $2.43B | $10.89B | $2.47B | $10.35B | $2.29B | $10.54B | $2.36B | $10.6B | $2.39B | $11.4B | $2.6B | $10.36B | $2.34B | $2.5B | $2.59B | $2.95B | $11.01B | $2.64B |
| QoQ Change | — | -61.6% | +162.3% | -60.1% | +187.6% | -61.2% | +184.8% | -64.2% | +159.3% | -70.0% | +224.3% | -72.3% | +286.6% | -73.4% | +251.5% | -75.6% | +309.2% | -77.0% | +329.3% | -77.0% | +347.4% | -77.3% | +319.0% | -77.9% | +361.3% | -77.7% | +350.0% | -77.5% | +377.4% | -77.1% | +298.0% | -77.4% | +6.7% | +3.6% | +13.8% | +273.6% | -76.0% |
| YoY Change | — | — | — | — | — | — | — | — | +18.3% | -64.5% | +14.4% | -68.3% | +7.0% | -71.5% | -9.4% | -77.9% | -2.6% | -77.5% | -1.0% | -77.2% | -4.9% | -78.4% | -3.4% | -78.7% | -1.4% | -78.0% | +0.2% | -77.4% | +4.7% | -76.1% | +0.2% | -77.4% | -76.3% | -75.6% | -74.1% | +6.2% | -74.6% |
Range$2.29B – $11.82B
CAGR-13.0%
Avg YoY Growth-40.5%
Median YoY Growth-68.3%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Thermo Fisher Scientific's life sciences solutions — consolidated revenues?
- Thermo Fisher Scientific (TMO) reported life sciences solutions — consolidated revenues of $2.64B in Q1 2026.
- How has Thermo Fisher Scientific's life sciences solutions — consolidated revenues changed year-over-year?
- Thermo Fisher Scientific's life sciences solutions — consolidated revenues decreased by 74.6% year-over-year, from $10.36B to $2.64B.
- What does life sciences solutions — consolidated revenues mean?
- Total sales generated by the life sciences segment before any expenses.